世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

APACがん免疫療法市場 - 2032年までの産業動向と予測


APAC Cancer Immunotherapy Market - Industry Trends and Forecast to 2032

アジア太平洋地域のがん免疫療法市場は、2023年の96億6,965万米ドルから2031年には285億2,761万米ドルに達し、2024年から2031年の予測期間中に年平均成長率15.4％で成長すると予測されている。 市場セグメンテー... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年12月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		321 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

アジア太平洋地域のがん免疫療法市場は、2023年の96億6,965万米ドルから2031年には285億2,761万米ドルに達し、2024年から2031年の予測期間中に年平均成長率15.4％で成長すると予測されている。
市場セグメンテーション
アジア太平洋地域の癌免疫療法市場：製品タイプ別（チェックポイント阻害剤、モノクローナル抗体、ワクチン、細胞療法、免疫調節剤、癌溶解性ウイルス）、用途別（肺癌、乳癌、黒色腫、骨髄腫、前立腺癌、卵巣癌、子宮頸癌、胃癌、大腸癌、頭頸部癌、その他）、エンドユーザー（病院、オンコロジークリニック、在宅医療、その他）、剤形（静脈内投与、筋肉内投与、経口投与）、流通チャネル（直接入札、小売販売、薬局）、国（中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、インドネシア、フィリピン、マレーシア、ニュージーランド、アジア太平洋地域その他） - 産業動向と2031年までの予測


アジア太平洋地域のがん免疫療法市場ダイナミクスの概要

促進要因
- がん罹患率の上昇

阻害要因
- 免疫関連の有害事象の増加

機会

- 併用療法への傾向の高まり

市場プレイヤー

アジア太平洋地域のがん免疫療法市場に参入している主な市場プレイヤーを以下に挙げる：

- メルク社
- F.ホフマン・ラ・ロシュ社
- ブリストル・マイヤーズ スクイブ社
- ヤンセンファーマ
- アストラゼネカ
- ギリアド・サイエンシズ
- イーライリリー・アンド・カンパニー
- アムジェン社
- ノバルティスAG
- GSK
- ファイザー
- インサイト


ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 103
4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105
5 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106
6 MARKET OVERVIEW 114
6.1 DRIVERS 116
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121
7 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE 122
7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
7.3.1 NAKED MONOCLONAL ANTIBODIES 129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
7.4.1 PROPHYLACTIC VACCINES 131
7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
7.6.1 INTERFERONS 133
7.6.2 INTERLEUKINS 133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134
8 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY END USER 135
8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141
9 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142
9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
9.4.1 HOSPITAL 148
9.4.2 RETAIL 148
9.4.3 ONLINE 148
10 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY FORM 149
10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154
11 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
11.1 OVERVIEW 156
11.2 LUNG CANCER 159
11.2.1 CHECKPOINT INHIBITORS 160
11.2.2 MONOCLONAL ANTIBODIES 160
11.2.3 CELL THERAPIES 160
11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
11.3.1 CHECKPOINT INHIBITORS 161
11.3.2 MONOCLONAL ANTIBODIES 161
11.3.3 CELL THERAPIES 162
11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
11.4.1 CHECKPOINT INHIBITORS 163
11.4.2 MONOCLONAL ANTIBODIES 163
11.4.3 CELL THERAPIES 163
11.4.4 IMMUNOMODULATORS 163
11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
11.5.1 CHECKPOINT INHIBITORS 164
11.5.2 MONOCLONAL ANTIBODIES 164
11.5.3 CELL THERAPIES 164
11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
11.6.1 CHECKPOINT INHIBITORS 165
11.6.2 MONOCLONAL ANTIBODIES 166
11.6.3 CELL THERAPIES 166
11.6.4 IMMUNOMODULATORS 166
11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
11.7.1 CHECKPOINT INHIBITORS 167
11.7.2 MONOCLONAL ANTIBODIES 167
11.7.3 CELL THERAPIES 167
11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
11.8.1 CHECKPOINT INHIBITORS 168
11.8.2 MONOCLONAL ANTIBODIES 168
11.8.3 VACCINES 169
11.8.4 CELL THERAPIES 169
11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
11.9.1 CHECKPOINT INHIBITORS 170
11.9.2 MONOCLONAL ANTIBODIES 170
11.9.3 CELL THERAPIES 170
11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
11.10.1 CHECKPOINT INHIBITORS 171
11.10.2 MONOCLONAL ANTIBODIES 171
11.10.3 CELL THERAPIES 171
11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
11.11.1 CHECKPOINT INHIBITORS 172
11.11.2 MONOCLONAL ANTIBODIES 172
11.11.3 CELL THERAPIES 172
11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
11.12.1 CHECKPOINT INHIBITORS 173
11.12.2 MONOCLONAL ANTIBODIES 173
11.12.3 VACCINES 174
11.12.4 CELL THERAPIES 174
11.12.5 IMMUNOMODULATORS 174
12 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY REGION 175
12.1 ASIA-PACIFIC 177
12.1.1 CHINA 186
12.1.2 JAPAN 194
12.1.3 INDIA 202
12.1.4 SOUTH KOREA 210
12.1.5 AUSTRALIA 218
12.1.6 SINGAPORE 227
12.1.7 THAILAND 236
12.1.8 INDONESIA 244
12.1.9 PHILIPPINES 253
12.1.10 MALAYSIA 262
12.1.11 VIETNAM 270
12.1.12 REST OF ASIA-PACIFIC 278
13 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 279
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 279
14 SWOT ANALYSIS 280
15 COMPANY PROFILES 281
15.1 MERCK & CO., INC. 281
15.1.1 COMPANY SNAPSHOT 281
15.1.2 REVENUE ANALYSIS 281
15.1.3 COMPANY SHARE ANALYSIS 282
15.1.4 PRODUCT PORTFOLIO 282
15.1.5 RECENT DEVELOPMENTS 282
15.2 F. HOFFMANN-LA ROCHE LTD 283
15.2.1 COMPANY SNAPSHOT 283
15.2.2 REVENUE ANALYSIS 283
15.2.3 COMPANY SHARE ANALYSIS 284
15.2.4 PRODUCT PORTFOLIO 284
15.2.5 RECENT DEVELOPMENTS 284
15.3 BRISTOL-MYERS SQUIBB COMPANY 286
15.3.1 COMPANY SNAPSHOT 286
15.3.2 REVENUE ANALYSIS 286
15.3.3 COMPANY SHARE ANALYSIS 287
15.3.4 PRODUCT PORTFOLIO 287
15.3.5 RECENT DEVELOPMENTS 288
15.4 JANSSEN ASIA PACIFIC SERVICES, LLC 289
15.4.1 COMPANY SNAPSHOT 289
15.4.2 REVENUE ANALYSIS 289
15.4.3 COMPANY SHARE ANALYSIS 290
15.4.4 PRODUCT PORTFOLIO 290
15.4.5 RECENT DEVELOPMENTS 291
15.5 ASTRAZENECA 292
15.5.1 COMPANY SNAPSHOT 292
15.5.2 REVENUE ANALYSIS 292
15.5.3 COMPANY SHARE ANALYSIS 293
15.5.4 PRODUCT PORTFOLIO 293
15.5.5 RECENT DEVELOPMENTS 294
15.6 ABBVIE INC. 295
15.6.1 COMPANY SNAPSHOT 295
15.6.2 PIPELINE PORTFOLIO 295
15.6.3 RECENT DEVELOPMENTS 295
15.7 AMGEN INC. 296
15.7.1 COMPANY SNAPSHOT 296
15.7.2 REVENUE ANALYSIS 297
15.7.3 PIPELINE PORTFOLIO 297
15.7.4 PRODUCT PORTFOLIO 298
15.7.5 RECENT DEVELOPMENTS 298
15.8 ATARA BIOTHERAPEUTICS, INC. 299
15.8.1 COMPANY SNAPSHOT 299
15.8.2 PIPELINE PORTFOLIO 299
15.8.3 RECENT DEVELOPMENTS 299
15.9 BAYER AG 300
15.9.1 COMPANY SNAPSHOT 300
15.9.2 PIPELINE PORTFOLIO 300
15.9.3 RECENT DEVELOPMENTS 300
15.10 CELLDEX THERAPEUTICS. 302
15.10.1 COMPANY SNAPSHOT 302
15.10.2 PIPELINE PORTFOLIO 302
15.10.3 RECENT DEVELOPMENTS 302
15.11 CELLECTIS 303
15.11.1 COMPANY SNAPSHOT 303
15.11.2 PIPELINE PORTFOLIO 303
15.11.3 RECENT DEVELOPMENTS 303
15.12 GILEAD SCIENCES, INC. 304
15.12.1 COMPANY SNAPSHOT 304
15.12.2 REVENUE ANALYSIS 304
15.12.3 PRODUCT PORTFOLIO 305
15.12.4 RECENT DEVELOPMENTS 305
15.13 GSK PLC. 306
15.13.1 COMPANY SNAPSHOT 306
15.13.2 REVENUE ANALYSIS 306
15.13.3 PRODUCT PORTFOLIO 307
15.13.4 RECENT DEVELOPMENTS 307
15.14 INCYTE. 308
15.14.1 COMPANY SNAPSHOT 308
15.14.2 REVENUE ANALYSIS 308
15.14.3 PRODUCT PORTFOLIO 309
15.14.4 RECENT DEVELOPMENTS 309
15.15 LILLY. 310
15.15.1 COMPANY SNAPSHOT 310
15.15.2 REVENUE ANALYSIS 311
15.15.3 PRODUCT PORTFOLIO 311
15.15.4 RECENT DEVELOPMENTS 312
15.16 NOVARTIS AG 313
15.16.1 COMPANY SNAPSHOT 313
15.16.2 REVENUE ANALYSIS 313
15.16.3 PIPELINE PORTFOLIO 314
15.16.4 PRODUCT PORTFOLIO 314
15.16.5 RECENT DEVELOPMENTS 314
15.17 PFIZER INC. 315
15.17.1 COMPANY SNAPSHOT 315
15.17.2 REVENUE ANALYSIS 315
15.17.3 PRODUCT PORTFOLIO 316
15.17.4 RECENT DEVELOPMENTS 316
16 QUESTIONNAIRE 317
17 RELATED REPORTS 321
 

　

ページTOPに戻る


　

Summary

The Asia-Pacific cancer immunotherapy market is expected to reach USD 28,527.61 million by 2031 from USD 9,669.65 million in 2023, growing at a CAGR of 15.4% during the forecast period of 2024 to 2031.
Market Segmentation
Asia-Pacific Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031


Overview of Asia-Pacific Cancer Immunotherapy Market Dynamics

Driver
• Rising prevalence of cancer incidences

Restraint
• Increasing occurrence of immune-related adverse events

Opportunity

• Growing trend towards combination therapies

Market Players

Some of the major market players operating in the Asia-Pacific cancer immunotherapy market are listed below:

• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Janssen Pharmaceutical
• AstraZeneca
• Gilead Sciences, Inc.
• Eli Lilly and Company
• Amgen Inc.
• Novartis AG
• GSK
• Pfizer Inc.
• Incyte



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 83
1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85
2 MARKET SEGMENTATION 89
2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 103
4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105
5 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106
6 MARKET OVERVIEW 114
6.1 DRIVERS 116
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121
7 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE 122
7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
7.3.1 NAKED MONOCLONAL ANTIBODIES 129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
7.4.1 PROPHYLACTIC VACCINES 131
7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
7.6.1 INTERFERONS 133
7.6.2 INTERLEUKINS 133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134
8 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY END USER 135
8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141
9 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142
9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
9.4.1 HOSPITAL 148
9.4.2 RETAIL 148
9.4.3 ONLINE 148
10 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY FORM 149
10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154
11 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
11.1 OVERVIEW 156
11.2 LUNG CANCER 159
11.2.1 CHECKPOINT INHIBITORS 160
11.2.2 MONOCLONAL ANTIBODIES 160
11.2.3 CELL THERAPIES 160
11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
11.3.1 CHECKPOINT INHIBITORS 161
11.3.2 MONOCLONAL ANTIBODIES 161
11.3.3 CELL THERAPIES 162
11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
11.4.1 CHECKPOINT INHIBITORS 163
11.4.2 MONOCLONAL ANTIBODIES 163
11.4.3 CELL THERAPIES 163
11.4.4 IMMUNOMODULATORS 163
11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
11.5.1 CHECKPOINT INHIBITORS 164
11.5.2 MONOCLONAL ANTIBODIES 164
11.5.3 CELL THERAPIES 164
11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
11.6.1 CHECKPOINT INHIBITORS 165
11.6.2 MONOCLONAL ANTIBODIES 166
11.6.3 CELL THERAPIES 166
11.6.4 IMMUNOMODULATORS 166
11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
11.7.1 CHECKPOINT INHIBITORS 167
11.7.2 MONOCLONAL ANTIBODIES 167
11.7.3 CELL THERAPIES 167
11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
11.8.1 CHECKPOINT INHIBITORS 168
11.8.2 MONOCLONAL ANTIBODIES 168
11.8.3 VACCINES 169
11.8.4 CELL THERAPIES 169
11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
11.9.1 CHECKPOINT INHIBITORS 170
11.9.2 MONOCLONAL ANTIBODIES 170
11.9.3 CELL THERAPIES 170
11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
11.10.1 CHECKPOINT INHIBITORS 171
11.10.2 MONOCLONAL ANTIBODIES 171
11.10.3 CELL THERAPIES 171
11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
11.11.1 CHECKPOINT INHIBITORS 172
11.11.2 MONOCLONAL ANTIBODIES 172
11.11.3 CELL THERAPIES 172
11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
11.12.1 CHECKPOINT INHIBITORS 173
11.12.2 MONOCLONAL ANTIBODIES 173
11.12.3 VACCINES 174
11.12.4 CELL THERAPIES 174
11.12.5 IMMUNOMODULATORS 174
12 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY REGION 175
12.1 ASIA-PACIFIC 177
12.1.1 CHINA 186
12.1.2 JAPAN 194
12.1.3 INDIA 202
12.1.4 SOUTH KOREA 210
12.1.5 AUSTRALIA 218
12.1.6 SINGAPORE 227
12.1.7 THAILAND 236
12.1.8 INDONESIA 244
12.1.9 PHILIPPINES 253
12.1.10 MALAYSIA 262
12.1.11 VIETNAM 270
12.1.12 REST OF ASIA-PACIFIC 278
13 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 279
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 279
14 SWOT ANALYSIS 280
15 COMPANY PROFILES 281
15.1 MERCK & CO., INC. 281
15.1.1 COMPANY SNAPSHOT 281
15.1.2 REVENUE ANALYSIS 281
15.1.3 COMPANY SHARE ANALYSIS 282
15.1.4 PRODUCT PORTFOLIO 282
15.1.5 RECENT DEVELOPMENTS 282
15.2 F. HOFFMANN-LA ROCHE LTD 283
15.2.1 COMPANY SNAPSHOT 283
15.2.2 REVENUE ANALYSIS 283
15.2.3 COMPANY SHARE ANALYSIS 284
15.2.4 PRODUCT PORTFOLIO 284
15.2.5 RECENT DEVELOPMENTS 284
15.3 BRISTOL-MYERS SQUIBB COMPANY 286
15.3.1 COMPANY SNAPSHOT 286
15.3.2 REVENUE ANALYSIS 286
15.3.3 COMPANY SHARE ANALYSIS 287
15.3.4 PRODUCT PORTFOLIO 287
15.3.5 RECENT DEVELOPMENTS 288
15.4 JANSSEN ASIA PACIFIC SERVICES, LLC 289
15.4.1 COMPANY SNAPSHOT 289
15.4.2 REVENUE ANALYSIS 289
15.4.3 COMPANY SHARE ANALYSIS 290
15.4.4 PRODUCT PORTFOLIO 290
15.4.5 RECENT DEVELOPMENTS 291
15.5 ASTRAZENECA 292
15.5.1 COMPANY SNAPSHOT 292
15.5.2 REVENUE ANALYSIS 292
15.5.3 COMPANY SHARE ANALYSIS 293
15.5.4 PRODUCT PORTFOLIO 293
15.5.5 RECENT DEVELOPMENTS 294
15.6 ABBVIE INC. 295
15.6.1 COMPANY SNAPSHOT 295
15.6.2 PIPELINE PORTFOLIO 295
15.6.3 RECENT DEVELOPMENTS 295
15.7 AMGEN INC. 296
15.7.1 COMPANY SNAPSHOT 296
15.7.2 REVENUE ANALYSIS 297
15.7.3 PIPELINE PORTFOLIO 297
15.7.4 PRODUCT PORTFOLIO 298
15.7.5 RECENT DEVELOPMENTS 298
15.8 ATARA BIOTHERAPEUTICS, INC. 299
15.8.1 COMPANY SNAPSHOT 299
15.8.2 PIPELINE PORTFOLIO 299
15.8.3 RECENT DEVELOPMENTS 299
15.9 BAYER AG 300
15.9.1 COMPANY SNAPSHOT 300
15.9.2 PIPELINE PORTFOLIO 300
15.9.3 RECENT DEVELOPMENTS 300
15.10 CELLDEX THERAPEUTICS. 302
15.10.1 COMPANY SNAPSHOT 302
15.10.2 PIPELINE PORTFOLIO 302
15.10.3 RECENT DEVELOPMENTS 302
15.11 CELLECTIS 303
15.11.1 COMPANY SNAPSHOT 303
15.11.2 PIPELINE PORTFOLIO 303
15.11.3 RECENT DEVELOPMENTS 303
15.12 GILEAD SCIENCES, INC. 304
15.12.1 COMPANY SNAPSHOT 304
15.12.2 REVENUE ANALYSIS 304
15.12.3 PRODUCT PORTFOLIO 305
15.12.4 RECENT DEVELOPMENTS 305
15.13 GSK PLC. 306
15.13.1 COMPANY SNAPSHOT 306
15.13.2 REVENUE ANALYSIS 306
15.13.3 PRODUCT PORTFOLIO 307
15.13.4 RECENT DEVELOPMENTS 307
15.14 INCYTE. 308
15.14.1 COMPANY SNAPSHOT 308
15.14.2 REVENUE ANALYSIS 308
15.14.3 PRODUCT PORTFOLIO 309
15.14.4 RECENT DEVELOPMENTS 309
15.15 LILLY. 310
15.15.1 COMPANY SNAPSHOT 310
15.15.2 REVENUE ANALYSIS 311
15.15.3 PRODUCT PORTFOLIO 311
15.15.4 RECENT DEVELOPMENTS 312
15.16 NOVARTIS AG 313
15.16.1 COMPANY SNAPSHOT 313
15.16.2 REVENUE ANALYSIS 313
15.16.3 PIPELINE PORTFOLIO 314
15.16.4 PRODUCT PORTFOLIO 314
15.16.5 RECENT DEVELOPMENTS 314
15.17 PFIZER INC. 315
15.17.1 COMPANY SNAPSHOT 315
15.17.2 REVENUE ANALYSIS 315
15.17.3 PRODUCT PORTFOLIO 316
15.17.4 RECENT DEVELOPMENTS 316
16 QUESTIONNAIRE 317
17 RELATED REPORTS 321
 

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

Data Bridge Market Research社の医薬分野での最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15　10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.